Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: omega-3-acid ethyl esters

« Back to Dashboard
Omega-3-acid ethyl esters is the generic ingredient in three branded drugs marketed by Smithkline Beecham, Apotex Inc, Par Pharm Inc, Teva Pharms Usa, and Trygg, and is included in five NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

This ingredient has thirty-four patent family members in twenty-three countries.

There are eleven drug master file entries for omega-3-acid ethyl esters. Seven suppliers are listed for this compound.

Summary for Generic Name: omega-3-acid ethyl esters

Tradenames:3
Patents:1
Applicants:5
NDAs:5
Drug Master File Entries: see list11
Suppliers: see list7
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Pharmacology for Ingredient: omega-3-acid ethyl esters

Clinical Trials for: omega-3-acid ethyl esters

Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension
Status: Completed Condition: Hypertriglyceridemia

Evaluation of Efficacy and Safety of Combined Omacor (Omega-3-acid Ethyl Esters) and Simvastatin Therapy in Hypertriglyceridemic Subjects
Status: Completed Condition: Hypertriglyceridemia

Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia
Status: Recruiting Condition: Hyperlipidemia, Familial Combined

Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia
Status: Completed Condition: Hypertriglyceridemia

An Efficacy and Safety Study of Omacor® in Taiwanese Hypertriglyceridemic Patients
Status: Completed Condition: Hypertriglyceridemia

A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™
Status: Completed Condition: Hypertriglyceridemia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
You have an error in your SQL syntax; check the manual that corresponds to your MySQL server version for the right syntax to use near 'LIMIT 5' at line 4